Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237


Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open Esophagectomy for Patients With Esophageal Cancer, Analysis of a Multicenter, Open-label, Randomized Phase III Controlled Trial: The MIRO Trial.

Mariette C, Markar S, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, D'Journo XB, Brigand C, Perniceni T, Carrere N, Mabrut JY, Msika S, Peschaud F, Prudhomme M, Bonnetain F, Piessen G; FRENCH, FREGAT.

Ann Surg. 2019 Aug 9. doi: 10.1097/SLA.0000000000003559. [Epub ahead of print]


Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.

Charton E, Bachet JB, Hammel P, Desramé J, Chibaudel B, Cohen R, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Guerin-Meyer V, Taieb J, Volet J, Louvet C, Anota A, Bonnetain F.

Cancer Med. 2019 Sep;8(11):5079-5088. doi: 10.1002/cam4.2311. Epub 2019 Jul 17.


PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study.

Gaiffe E, Crepin T, Bamoulid J, Courivaud C, Büchler M, Cassuto E, Albano L, Chemouny JM, Choukroun G, Hazzan M, Kessler L, Legendre C, Le Meur Y, Ouali N, Thierry A, Anota A, Nerich V, Limat S, Bonnetain F, Vernerey D, Ducloux D.

Trials. 2019 Jun 21;20(1):375. doi: 10.1186/s13063-019-3392-6.


Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.

Kerckhove N, Busserolles J, Stanbury T, Pereira B, Plence V, Bonnetain F, Krakowski I, Eschalier A, Pezet D, Balayssac D.

BMJ Open. 2019 Jun 9;9(6):e027770. doi: 10.1136/bmjopen-2018-027770.


Health-related quality of life as an endpoint in oncology phase I trials: a systematic review.

Fiteni F, Ray IL, Ousmen A, Isambert N, Anota A, Bonnetain F.

BMC Cancer. 2019 Apr 16;19(1):361. doi: 10.1186/s12885-019-5579-3.


Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment.

Antoun S, Morel H, Souquet PJ, Surmont V, Planchard D, Bonnetain F, Foucher P, Egenod T, Krakowski I, Gaudin H, Debieuvre D.

J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):782-793. doi: 10.1002/jcsm.12418. Epub 2019 Apr 1.


RILA blood biomarker as a predictor of radiation-induced sarcoma in a matched cohort study.

Mirjolet C, Merlin JL, Truc G, Noël G, Thariat J, Domont J, Sargos P, Renard-Oldrini S, Ray-Coquard I, Liem X, Chevreau C, Lagrange JL, Mahé MA, Collin F, Bonnetain F, Bertaut A, Maingon P.

EBioMedicine. 2019 Mar;41:420-426. doi: 10.1016/j.ebiom.2019.02.031. Epub 2019 Mar 1.


Propensity score methods and regression adjustment for analysis of nonrandomized studies with health-related quality of life outcomes.

Cottone F, Anota A, Bonnetain F, Collins GS, Efficace F.

Pharmacoepidemiol Drug Saf. 2019 May;28(5):690-699. doi: 10.1002/pds.4756. Epub 2019 Feb 19.


The role of trait emotional intelligence in quality of life, anxiety and depression symptoms after surgery for esophageal or gastric cancer: A French national database FREGAT.

Baudry AS, Anota A, Mariette C, Bonnetain F, Renaud F, Piessen G, Christophe V; and the FREGAT Working Group.

Psychooncology. 2019 Apr;28(4):799-806. doi: 10.1002/pon.5023. Epub 2019 Feb 27.


Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.

Chibaudel B, Bachet JB, André T, Auby D, Desramé J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V, Dauba J, Lledo G, Garcia ML, Dubreuil O, Hamed NB, Meurisse A, Larsen AK, Tijeras-Raballand A, Bonnetain F, De Gramont A.

Int J Oncol. 2019 Apr;54(4):1433-1445. doi: 10.3892/ijo.2019.4709. Epub 2019 Feb 1.


Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

Mouillet G, Fritzsch J, Paget-Bailly S, Pozet A, Es-Saad I, Meurisse A, Vernerey D, Mouyabi K, Berthod D, Bonnetain F, Anota A, Thiery-Vuillemin A.

Health Qual Life Outcomes. 2019 Feb 4;17(1):25. doi: 10.1186/s12955-019-1085-1.


Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology.

Cottone F, Deliu N, Collins GS, Anota A, Bonnetain F, Van Steen K, Cella D, Efficace F.

Qual Life Res. 2019 May;28(5):1315-1325. doi: 10.1007/s11136-018-02097-2. Epub 2019 Jan 18.


Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer.

Mariette C, Markar SR, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, D'Journo XB, Brigand C, Perniceni T, Carrère N, Mabrut JY, Msika S, Peschaud F, Prudhomme M, Bonnetain F, Piessen G; Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Group.

N Engl J Med. 2019 Jan 10;380(2):152-162. doi: 10.1056/NEJMoa1805101.


Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review.

Ousmen A, Touraine C, Deliu N, Cottone F, Bonnetain F, Efficace F, Brédart A, Mollevi C, Anota A.

Health Qual Life Outcomes. 2018 Dec 11;16(1):228. doi: 10.1186/s12955-018-1055-z. Review.


Surrogate endpoints in advanced sarcoma trials: a meta-analysis.

Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, Gronchi A, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pélissier S, Bellera C.

Oncotarget. 2018 Oct 2;9(77):34617-34627. doi: 10.18632/oncotarget.26166. eCollection 2018 Oct 2.


Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France.

Despiégel N, Touboul C, Flinois A, Saba G, Suzan F, Gonzalez-McQuire S, Bonnetain F.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e13-e28. doi: 10.1016/j.clml.2018.08.019. Epub 2018 Sep 5.


Psychometric validation of the French version of the Supportive Care Needs Survey for Partners and Caregivers of cancer patients.

Baudry AS, Anota A, Bonnetain F, Mariette C, Christophe V.

Eur J Cancer Care (Engl). 2019 Jan;28(1):e12896. doi: 10.1111/ecc.12896. Epub 2018 Aug 31.


Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.

Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Greimel E, Griebsch I, Groenvold M, Hamel JF, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Moinpour CM, Musoro JZ, O'Connor D, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Sridhara R, Taphoorn MJB, Velikova G, Coens C.

Clin Trials. 2018 Dec;15(6):624-630. doi: 10.1177/1740774518795637. Epub 2018 Aug 24.


Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.

Fenioux C, Louvet C, Charton E, Rozet F, Ropert S, Prapotnich D, Barret E, Sanchez-Salas R, Mombet A, Cathala N, Joulia ML, Molitor JL, Henriques J, Bonnetain F, Cathelineau X, Bennamoun M.

BJU Int. 2019 Feb;123(2):300-306. doi: 10.1111/bju.14511. Epub 2018 Sep 4.


Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER.

J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5.


Ethical leadership, professional caregivers' well-being, and patients' perceptions of quality of care in oncology.

Gillet N, Fouquereau E, Coillot H, Bonnetain F, Dupont S, Moret L, Anota A, Colombat P.

Eur J Oncol Nurs. 2018 Apr;33:1-7. doi: 10.1016/j.ejon.2018.01.002. Epub 2018 Jan 12.


Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD.

Bascoul-Mollevi C, Savina M, Anota A, Barbieri A, Azria D, Bonnetain F, Gourgou S.

Comput Methods Programs Biomed. 2018 May;158:153-159. doi: 10.1016/j.cmpb.2018.02.010. Epub 2018 Feb 17.


Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM.

Lancet Oncol. 2018 Mar;19(3):e151-e160. doi: 10.1016/S1470-2045(18)30098-6.


RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P.

Ann Oncol. 2018 May 1;29(5):1211-1219. doi: 10.1093/annonc/mdy061.


Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.

Guiu B, Jouve JL, Schmitt A, Minello A, Bonnetain F, Cassinotto C, Piron L, Cercueil JP, Loffroy R, Latournerie M, Wendremaire M, Lepage C, Boulin M.

J Hepatol. 2018 Jun;68(6):1163-1171. doi: 10.1016/j.jhep.2018.01.022. Epub 2018 Feb 8.


The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers.

Mariette C, Renaud F, Piessen G, Gele P, Copin MC, Leteurtre E, Delaeter C, Dib M, Clisant S, Harter V, Bonnetain F, Duhamel A, Christophe V, Adenis A; Fregat Working Group.

BMC Cancer. 2018 Feb 6;18(1):139. doi: 10.1186/s12885-018-3991-8.


The effects of work factors on nurses' job satisfaction, quality of care and turnover intentions in oncology.

Gillet N, Fouquereau E, Coillot H, Cougot B, Moret L, Dupont S, Bonnetain F, Colombat P.

J Adv Nurs. 2018 May;74(5):1208-1219. doi: 10.1111/jan.13524. Epub 2018 Feb 13.


Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.

Palle J, Tougeron D, Pozet A, Soularue E, Artru P, Leroy F, Dubreuil O, Sarabi M, Williet N, Manfredi S, Martin-Babau J, Rebischung C, Abdelghani MB, Evesque L, Dreanic J, Hautefeuille V, Louafi S, Sefrioui D, Savinelli F, Mabro M, Rousseau B, Lecaille C, Bouché O, Louvet C, Lecomte T, Bonnetain F, Taieb J, Zaanan A.

Oncotarget. 2017 Sep 8;8(60):101383-101393. doi: 10.18632/oncotarget.20711. eCollection 2017 Nov 24.


Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.

Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F.

Cancer. 2018 Mar 15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12.


Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study.

Turpin A, Paget-Bailly S, Ploquin A, Hollebecque A, Peugniez C, El-Hajbi F, Bonnetain F, Hebbar M.

Clin Colorectal Cancer. 2018 Mar;17(1):e99-e107. doi: 10.1016/j.clcc.2017.10.001. Epub 2017 Oct 19.


The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer.

Manneville F, Rotonda C, Conroy T, Bonnetain F, Guillemin F, Omorou AY.

Cancer. 2018 Feb 15;124(4):797-806. doi: 10.1002/cncr.31108. Epub 2017 Nov 8.


Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7).

Brédart A, Anota A, Young T, Tomaszewski KA, Arraras JI, Moura De Albuquerque Melo H, Schmidt H, Friend E, Bergenmar M, Costantini A, Vassiliou V, Hureaux J, Marchal F, Tomaszewska IM, Chie WC, Ramage J, Beaudeau A, Conroy T, Bleiker E, Kulis D, Bonnetain F, Aaronson NK; EORTC Quality of Life Group.

Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12786. Epub 2017 Nov 2.


Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE).

Bennouna J, Falchero L, Schott R, Bonnetain F, Coudert M, Ben Hadj Yahia B, Chouaid C.

Oncology. 2018;94(1):55-64. doi: 10.1159/000480702. Epub 2017 Oct 25.


Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C.

BMC Cancer. 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0.


Chemoradiation in elderly esophageal cancer patients: rationale and design of a phase I/II multicenter study (OSAGE).

Servagi-Vernat S, Créhange G, Bonnetain F, Mertens C, Brain E, Bosset JF.

BMC Cancer. 2017 Jul 13;17(1):483. doi: 10.1186/s12885-017-3465-4.


A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.

Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M, Dumoulin G, Vernerey D, Pivot X, Mougin F.

BMC Cancer. 2017 Jun 19;17(1):425. doi: 10.1186/s12885-017-3420-4.


Cancer de l’ovaire : la rechute précoce.

Pautier P, Kalbacher E, de la Motte Rouge T, Bonnetain F, Lesoin A.

Bull Cancer. 2017 May;104 Suppl 1:S32-S38. doi: 10.1016/S0007-4551(17)30160-1. French.


Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes-An ESDO Report.

Van Cutsem E, De Gramont A, Henning G, Rougier P, Bonnetain F, Seufferlein T.

Cancers (Basel). 2017 May 26;9(6). pii: E59. doi: 10.3390/cancers9060059. Review.


Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.

Auclin E, Zaanan A, Vernerey D, Douard R, Gallois C, Laurent-Puig P, Bonnetain F, Taieb J.

Ann Oncol. 2017 May 1;28(5):958-968. doi: 10.1093/annonc/mdx030. Review.


How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.

Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A.

Ann Oncol. 2017 Sep 1;28(9):2077-2085. doi: 10.1093/annonc/mdx191. Review.


Surrogate endpoints for overall survival in lung cancer trials: a review.

Fiteni F, Westeel V, Bonnetain F.

Expert Rev Anticancer Ther. 2017 May;17(5):447-454. doi: 10.1080/14737140.2017.1316196. Epub 2017 Apr 12. Review.


Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C.

Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346. doi: 10.1016/S2468-1253(17)30046-8. Epub 2017 Feb 28.


Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.

Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx037.


Predictors of long-term functional outcome and health-related quality of life after out-of-hospital cardiac arrest.

Geri G, Dumas F, Bonnetain F, Bougouin W, Champigneulle B, Arnaout M, Carli P, Marijon E, Varenne O, Mira JP, Empana JP, Cariou A.

Resuscitation. 2017 Apr;113:77-82. doi: 10.1016/j.resuscitation.2017.01.028. Epub 2017 Feb 12.


Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomised controlled trial, the PEPs fatigue study.

Bourmaud A, Anota A, Moncharmont C, Tinquaut F, Oriol M, Trillet-Lenoir V, Bajard A, Parnalland S, Rotonda C, Bonnetain F, Pérol D, Chauvin F.

Br J Cancer. 2017 Mar 28;116(7):849-858. doi: 10.1038/bjc.2017.31. Epub 2017 Feb 14.


Care pathway of patients with metastatic pancreatic cancer in daily practice in France: Results from the REPERE national survey.

Hammel P, Coriat R, Lledo G, de Bausset M, Selosse M, Obled S, Bonnetain F.

Bull Cancer. 2017 Apr;104(4):321-331. doi: 10.1016/j.bulcan.2016.11.022. Epub 2017 Jan 11.


[Assessment of the quality of life with regard to health following a cancer diagnosis].

Es-Saad I, Paget-Bailly S, Fritzsch J, Mouillet G, Bonnetain F.

Rev Infirm. 2017 Jan;66(227):36-37. doi: 10.1016/j.revinf.2016.11.013. French.


Reply to Sorscher S.

Fiteni F, Bonnetain F.

Breast. 2017 Jun;33:203. doi: 10.1016/j.breast.2016.12.005. Epub 2016 Dec 23. No abstract available.


Erratum to: Development and validation of the FRAGIRE tool for assessment an older person's risk for frailty.

Vernerey D, Anota A, Vandel P, Paget-Bailly S, Dion M, Bailly V, Bonin M, Pozet A, Foubert A, Benetkiewicz M, Manckoundia P, Bonnetain F.

BMC Geriatr. 2016 Dec 9;16(1):212. No abstract available.


Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials.

Fiteni F, Paillard MJ, Westeel V, Bonnetain F.

Expert Rev Anticancer Ther. 2017 Feb;17(2):167-173. doi: 10.1080/14737140.2016.1271718. Epub 2016 Dec 23. Review.


Supplemental Content

Loading ...
Support Center